Kimberly K. Leslie

article 2024

Abstract PR003: The combination of the glucagon like peptide-1 receptor agonist semaglutide and the progestin levonorgestrel is highly effective in preclinical studies of endometrial cancer

·doi:10.1158/1557-3265.endo24-pr003

Abstract Obesity is a major risk factor for endometrial cancer (EC), and glucagon like peptide-1 receptor (GLP-1R) agonists such as semaglutide may be helpful to achieve weight loss during conservative treatment or for EC prevention. Proges…

article 2015

Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices

·doi:10.1016/j.ygyno.2015.10.023

ObjectiveTo examine hormone receptor expression levels and downstream gene activation in pre-treatment and post-treatment biopsies in a cohort of patients with endometrial pathology who were being conservatively managed with a progestin-con…

article 2015

FOXO1 expression could be a predictive marker of endometrial cancer progression in patients treated with progesterone-containing intra uterine device

·doi:10.1016/j.ygyno.2015.07.079

2011

Progesterone: the ultimate endometrial tumor suppressor.

Trends in endocrinology and metabolism: TEM ·doi:10.1016/j.tem.2011.01.005

The uterine endometrium is exquisitely sensitive to steroid hormones that act through well-described nuclear receptors. Estrogen drives epithelial proliferation, and progesterone inhibits growth and causes cell differentiation. The importan…

article 2008

Vascular endothelial growth factor pathway blockade in endometrial cancer